Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Helix Biopharma stock remained flat at $0.77 during midday trading on Thursday. The company has a 50 day simple moving average of $1.26 and a 200 day simple moving average of $1.61. Helix Biopharma has a 52-week low of $0.77 and a 52-week high of $1.73.
About Helix Biopharma
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.
Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth.
Further Reading
- Five stocks we like better than Helix Biopharma
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
